Inclusion Criteria:  Had onset of symptoms consistent with HS at least 6 months prior to Screening. Has had active HS for at least 2 months. Has ≥ 5 HS abscesses or inflammatory nodules at Screening. Agrees to maintain baseline wound care and antibiotic therapy, including oral antibiotics, for the duration of the trial. Agrees to use contraception  Exclusion Criteria:  Has other skin disease or condition that can interfere with HS assessment. Has a positive test for TB, HIV, hepatitis B and/or hepatitis C at Screening. Has a history of retinopathy or known clinically significant cardiovascular or hematologic conditions. Has taken any biologic drug within 3 serum half-lives. A list of potential biologics and their half-lives Has started oral antibiotics within 28 days of Study Day 1. Has, within 2 weeks prior to Day 1, received a medication prohibited based on cytochrome P450 (CYP3A4) interaction Has such extensive disease that, in the opinion of the Investigator, it is difficult to discriminate between active lesions and scarring. Has more than 15 active tunnels at Screening. Is pregnant, nursing or considering becoming pregnant. Has a history of malignancy except non-melanoma skin cancer or cervical carcinoma in situ.